anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To prepare a sheet-shaped pack material, capable of suppressing the suppuration of injuries which may occur after removal of sebum or aged keratin by compounding the obverse surface or the entire of a sheet-shaped pack material with a bactericidal agent and/or an antibacterial agent. SOLUTION: This peel off-type sheet-shaped pack material is obtained by compounding preferably the sticky adhesive layer of the utmost surface with a bactericidal agent and/or an antibacterial agent. Further, the compounding amount of the bactericidal agent or an antibacterial agent is, e.g. 0.05wt.% in the case of chlorhexidine glucuronate based on the entire weight of the pack material. As an example of a method for compounding the pack material with the bactericidal agent or the antibacterial agent, it is cited that a stock solution of the pack material mainly composed of an aqueous or alcohol solution of an adhesive agent is compounded with the bactericidal agent or the antibacterial agent, and subsequently the resultant solution is processed to form a sheet shape by using a device such as a doctor blade followed by drying.  Thus obtained pack material can prevent the suppuration of many injuries or hyperplasia which may occur after good removal of sebum.
PCT No. PCT/AU87/00427 Sec. 371 Date Sep. 22, 1988 Sec. 102(e) Date Sep. 22, 1988 PCT Filed Dec. 16, 1987 PCT Pub. No. WO88/04689 PCT Pub. Date Jun. 30, 1988.A DNA molecule is provided which comprises a nucleotide sequence substantially corresponding to all or a portion of the base sequence coding for the mitochondrial autoantigen of primary biliary cirrhosis. This DNA molecule may be linked to an expression control sequence. A synthetic peptide or polypeptide is provided which includes at least an amino acid sequence substantially as shown in FIG. 6 or FIG. 8. This synthetic peptide or polypeptide may be prepared by expression of a host cell which has been transformed with a recombinant DNA molecule as described above, or by chemical synthesis.
OBJECTIVE: We conducted a systematic review of all available evidence on the feasibility and safety of minimally invasive coronary artery bypass grafting (MICS CABG) in patients with multivessel coronary artery disease (CAD).
METHODS: A systematic literature search in PubMed, MEDLINE via Ovid, Embase, Scopus, and Web of Science was performed to identify all relevant studies evaluating outcomes of MICS CABG among patients with multivessel CAD and including at least 15 patients with no restriction on the publication date.
RESULTS: A total of 881 studies were identified, of which 26 studies met the eligibility criteria. The studies included a total of 7,556 patients. The average patient age was 63.3 years (range 49.5 to 69.0 years), male patients were an average of 77.8% (54.0% to 89.8%), and body mass index was 29.8 kg/m2 (24.5 to 30.1 kg/m2). Early mortality and stroke were on average 0.6% (range 0% to 2.0%) and 0.4% (range 0% to 1.3%), respectively. The average number of grafts was 2.8 (range 2.1 to 3.7). The average length of hospital stay was 5.6 days (range 3.1 to 9.3 days).
CONCLUSIONS: MICS CABG appears to be a safe method in well-selected patients with multivessel CAD. This approach is concentrated at dedicated centers, and there is no widespread application, although it has potential to be widely applicable as an alternative for surgical revascularization. However, large randomized controlled studies with longer follow-up are still required to compare the outcomes with conventional CABG and other revascularization strategies.
A composition for the relief of symptoms of teething in human children, and a method of its use, is disclosed. The composition includes effective amounts of the homeopathic ingredients Belladonna 3C, Chamomilla 3C and Coffea Cruda 3C, preferably combined with distilled water to form a solution. The solution is introduced into a flexible tube that is open at one end and sealed at another end. The open end is then sealed to form a water-tight pouch, which is then cooled such that the solution is frozen. In use, a pouch may be opened and the solution expelled partially from the tube in order to be orally administered to the gums of the child. The volume of solution in each pouch contains enough of the components of the solution to be effective at providing pain relief to the child experiencing teething pain, as the solution melts, while the cold temperature of the solution provides further pain relief for the child. A sweetener, artificial and natural flavors, and artificial colors may be included in the solution to enhance its taste and appearance.
FIELD: chemical technology, vitamins. SUBSTANCE: vitamin A acetate is synthesized by halogenation of diol-C 20  mono- and diacetates with hydrochloric acid at decreased temperature followed by dihydrohalogenation of synthesized chloroacetates at pH = 5.0-9.0 in the presence of alkaline metal iodide and treatment with reducing agent. After chlorination process an aqueous-acid layer is separated at (-5)-(+2) C and organic layer containing diol-C 20  chloroacetates is added to alkali aqueous solution directly that contains alkali metal iodide. Dihydrochlorination process is carried out in the presence of catalytic amount of iodide at mass ratio of diol-C 20  and iodide = 1:(0.02-0.04). Potassium or sodium iodide is used as alkaline metal iodide. Yield and content of the end product - 88.1% and 78.2%, respectively. EFFECT: increased yield, improved quality, decreased consumption of reagents. 5 cl, 2 tbl
A method for hydroenhancing fabrics is described. The method uses the force of pressurized liquid passing through elongated orifices (40) and impinging on the fabric (4). The pressurized liquid exits in a coherent or columnar fashion from elongated orifices that are generally rectangular or linear in shape. The elongated orifices can be arranged so as to produce various effects on a web of fabric, including striping, graduated shading and seer-suckering. The elongated orifices also facilitate the hydroenhancement of high- warp-count fabrics without streak or moire effects. Liquid filtration can be relaxed without clogging the orifices, because the elongated orifices permit larger solid objects to pass. The use of elongated orifices also enhances the energy efficiency of the hydroenhancement process.
Sweet breakfasts. Participants are asked to consume a sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
The application discloses a Faster R-CNN food classification and GL value identification method based on an attention mechanism SENEt. The method comprises the steps of acquiring a picture which is uploaded to a server by a user and contains a reference object, and detecting and identifying food by a Faster R-CNN algorithm based on an attention mechanism SENet. The attention mechanism enables the feature extraction network to use global information without being limited by local small-field-of-view information, and simultaneously effectively avoids the problems of gradient disappearance and degradation caused by the increase of the network depth. And inputting the food type and position and the reference object position into a trained linear regression model to predict the food volume. Calculating a Glycemic Load (GL) value of the food according to the type and the GI of the food, judging the edible type of the food, and generating a food edible suggestion. And finally, feeding the result back to the user.
Pharmaceutical and/or cosmetic compsns. contg. retinyl salicylate (I) or retinyl acetylsalicylate (II) are new. Also claimed is the prodn. of (I) and (II) by reacting retinol with salicylic or acetylsalicylic acid in a solvent, where the acid may be in the form of a reactive deriv., e.g, the acid chloride, anhydride, succinimidyl ester or p-nitrophenyl ester, or the reaction may be effected in the presence of DCC. Also claimed are processes for preparing compsn. as above.
Participants in the strength-training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in strength training 3 days per week for approximately 60 minutes each exercise session.
This project will introduce and evaluate an intervention designed to improve diagnostic decision making. The intervention will attempt to increase clinician mindfulness and reduce environmental distractions to promote system 2 thinking. A meta-cognitive intervention using a structured checklist will be evaluated to identify improvement in diagnostic and therapeutic decision-making and examine the role of mindfulness and architectural design in enhancing patient safety.

This a pretest-posttest design study that will be conducted with hospitalist physicians working at Michigan Medicine and/or the VA Ann Arbor Healthcare System. The proposed intervention will provide the participants with tools to help promote mindfulness and focus to assist with the diagnostic process. To reduce distraction, headphones to block out surrounding noise and table screens to limit distractions will be offered. To assist with diagnosis, a diagnostic checklist and use of a IPad to use an online diagnosis application will be provided.
PURPOSE:To provide a base for external drug, capable of raising the concentration of the drug component in the blood rapidly to the required level and keeping the concentration for a long period, and having stable shape, by combining a polyacrylic acid with a specific polyethylene glycol and using the mixture as a non-aqueous system. CONSTITUTION:An non-aqueous base for external drug, obtained by combining a polyacrylic acid with a polyethylene glycol having a molecular weight of >=200. The time necessary to raise the drug concentration in the blood to the peak can be controlled freely by adjusting the molecular weight of the polyethylene glycol to be added to the composition. The concentration of a drug (e.g. anti-inflammatory, analgesic, antipruritic, antidermatorycotic agents) can be raised within a short time, and maintained at the level for a long period. It is a transparent glossy gel stable to the temperature change. It has extremely low interaction with drugs, and can be used as an external drug by combining with various drugs.
Creatinine and NGAL have been used successfully in the follow-up of acute kidney injury. In our study, in order to show the effect of pneumoperitoneum on acute kidney injury in patients scheduled for laparoscopic surgery, NGAL and IGF-1 values will be measured before, after and 24 hours after pneumoperitoneum, and these values will be compared.
In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in VYVGART-treated patients. Hypersensitivity reactions were mild or moderate, occurred within one hour to three weeks of administration, and did not lead to treatment discontinuation.

Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with VYVGART. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation.

Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention. VYVGART is contraindicated in patients with a history of serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART [see Contraindications (4)].
Cyclophosphamide 1 gram/m\^2 administered 2-4 days prior to dose of 1-3x10\^7 huCART-meso cells/m\^2 via IV infusion on Day 0. This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells.
The long-term goal of this research program is to characterize the antecedents and mediators of morbid long-term outcomes in patients with sepsis. Despite successful early management, sepsis is a disease with a high incidence of chronic critical illness (CCI - intensive care unit stay ≥ 14 days with organ dysfunction) and morbid long-term outcomes (functional dependence or death at 1 year), which occur frequently in early survivors. Both the rapid identification of patients at risk for morbid outcomes and the development of novel therapies are crucial for improving outcomes after sepsis. High density lipoprotein (HDL) defends against sepsis-associated organ injury by: 1) neutralizing bacterial endotoxin, 2) modulating innate cellular immunity and preventing release of inflammatory cytokines, and 3) preventing endothelial cell activation and dysfunction. However, HDL can become dysfunctional (Dys-HDL) in the setting of inflammation, losing protective functions and becoming pro-inflammatory. Our preliminary results demonstrate that Dys-HDL is present in early sepsis and that persistent Dys-HDL elevation (first 48 hours) is associated with adverse outcomes (death, hospice or nursing home care). The overall goal of this proposal is to investigate and fully characterize the role of Dys-HDL in a diverse population of patients with both CA and HA-sepsis. The central hypothesis of this study is that structural and functional changes in HDL during sepsis are associated with the persistent presence of Dys-HDL as well as the inflammation and endothelial dysfunction that lead to acute organ dysfunction, CCI, and morbid long-term outcomes. To test this, we will enroll 160 patients in a two-site, prospective, longitudinal, cohort study.
This study will gather empirical evidence of the effectiveness of WOWii intervention in promoting changes in exercise behavior, fitness, and perceptions of exercise over the 16 week intervention as well as 2 months later for individuals living with SCI. The study staff will assess effectiveness by measuring participants (a) time spent each week doing aerobic exercise by self-report and objective monitoring, (b) aerobic capacity to assess fitness changes, and (c) self-reported perceptions of exercise barriers and self-efficacy at baseline, 4 months, and 6 months.

Participants will be randomly assigned to an experimental (WOWii) or a wait-list control group in one of four cohorts over a two-year period. This was an effective strategy in our previous trial in helping us achieve the full sample size. We will use a blocked randomization procedure to assure equal distribution of those with paraplegia and tetraplegia. Four cohorts will be enrolled over two years, with each having up to 36 people. This allows for up to 18 participants in the experimental and control groups, which permits us to offer two different time options for participants to attend the weekly meetings, as our video conferencing software allows up to 10 people to participate in the group video chat. Each cohort will be divided into two groups of 18 study participants as experimental and wait-list control groups. The experimental group will be divided into two groups of nine participants. Each cohort will begin the intervention at the same time and attend weekly calls together. All participants will undergo a pre-screen assessment which includes eligibility assessment. Participants will undergo 2 in-person fitness testing assessments at baseline at the end of the 16 week internet intervention with online meetings, before or during which they will complete an online survey and follow. A third follow up assessment will be conducted as an online survey at 6 months, which is 2 months after the intervention is complete, and an exit survey will be conducted individually over the phone after within one week of completing the final online survey. The wait-list control group will be offered the intervention at the end of the 6 month period. Due to low enrollment numbers, we will likely add a 5th cohort for enrollment.
Ceftaroline fosamil is a time-dependent, hydrophilic, bactericidal fifth generation cephalosporin that was FDA approved in 2010 for community acquired pneumonia and skin and skin structure infections. Ceftaroline is FDA approved for both Gram-positive and Gram-negative organisms. Gram-positive organisms covered are Staphylococcus aureus (methicillin resistant and methicillin sensitive strains), Streptococcus agalactiae, Streptococcus pneumonia, and Streptococcus pyogenes. Gram-negative coverage includes Escherichia coli, Haemophilus influenza, Klebsiella pneumonia, and Klebsiella oxytoca. In order for ceftaroline to exhibit effective bacterial killing, it requires that a certain percentage of the dosing interval is spent above the MIC.

Dosing of ceftaroline in patients with chronic kidney disease is defined, but there is no data on pharmacokinetics and pharmacodynamics of the drug in patients receiving continuous renal replacement therapy (CRRT). The purpose of this study is to determine pharmacokinetics and pharmacodynamics of ceftaroline in a critically ill patient population receiving CRRT, in order to define a dosing recommendation in this population. CRRT modes that patients may be receiving in this trial include: continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD), and continuous veno-venous hemodiafiltration (CVVHDF).
Mirror Therapy is a form of upper limb therapy in stroke, which consists on showing the mirrored symmetric movement of the unimpaired side using a mirror placed in the medial sagittal plane. The illusion of movement corresponding to the impaired extremity could facilitate neuroplasticity, and assists patients in regaining certain lost motor functions. Recent studies have shown the potential and benefit of translating this effective therapy in an immersive virtual reality (VR) environment, using head mounted display and hand tracking systems. This work investigates the feasibility to use myoelectric control in an immersive VR environment for the mirror therapy to accomplish a funtional task. Surface electromyography sensors were used to measure muscle activation and detect user intention to perform grasping actions in two visual feedback configurations: unimanual and bimanual. Even though in both conditions the virtual mirrored hand is controlled by the healthy hand, the latter creates the illusion that two functional hands cooperate for grasping. A total of 18 healthy subjects participated in the evaluation of the environment, control method and a comparison between the two configurations. This includes self-rating surveys and performance metrics. Results from the Simulator Sickness Questionnaire showed negligible adverse symptoms related to the use of the VR-application proposed. Positive outcomes from the System Usability Scale and Presence Questionnaire affirmed its feasible as a form of therapy for the rehabilitation of hemiparetic stroke patients. Although the adapted Box and Blocks Test proved immediate training-induced learning, performance measures revealed no significant distinctions between visual feedback configurations.
The present invention relates to fungus solid zymogen powder for foods and medicine. The fungus solid zymogen powder mainly contains components of cordyceps, microspore Coprinus comatus, laetiporus sulphureus (fr.)murrill, sparassis radicata, gleoestereum incarnatum and ganoderma powder, components are matched mutually and cooperate with each other, the components are mixed evenly into zymogen powder according to the appropriate weight proportion, and the present invention is suitable for being used as foods for health care medicine for people who suffer diabetes, nephrosis and gastrointestinal system diseases. The present invention belongs to a pure biological preparation without any chemical substance or additive harmful to human bodies. The effects of disease treatment, body building, improvement of the integral quality of bodies, enhancement of the immunity of bodies and prevention of diseases can be reached by that patients eat the zymogen powder. The present invention has the functions of kidney protection, lung benefiting, blood sugar lowering, blood lipid reduction and improvement of the gstrointestinal tract, has anticancer activity, and has obvious therapeutic effects to diabetes, nephrosis and stomach intestine disturbance. The present invention obtains zymogen powder in a solid fermentation technology and has the advantages of short production period, weather resistance, less investment, obvious effect, low production cost, etc.
Pattern recognition receptors (PRRs) induce host defense but can also induce exacerbated inflammatory responses. This raises the question of whether other mechanisms are also involved in early host defense. Using transcriptome analysis of disrupted transcripts in herpes simplex virus (HSV)-infected cells, we find that HSV infection disrupts the hypoxia-inducible factor (HIF) transcription network in neurons and epithelial cells. Importantly, HIF activation leads to control of HSV replication. Mechanistically, HIF activation induces autophagy, which is essential for antiviral activity. HSV-2 infection in vivo leads to hypoxia in CNS neurons, and mice with neuron-specific HIF1/2α deficiency exhibit elevated viral load and augmented PRR signaling and inflammatory gene expression in the CNS after HSV-2 infection. Data from human stem cell-derived neuron and microglia cultures show that HIF also exerts antiviral and inflammation-restricting activity in human CNS cells. Collectively, the HIF transcription factor system senses virus-induced hypoxic stress to induce cell-intrinsic antiviral responses and limit inflammation.
The invention relates to a bicycle seat which differs first of all from conventional seats in that it comprises a bar-like, at least partially round shape having a diameter of at least 8 cm, and that it is arranged in a crosswise manner in relation to the riding direction. Such a configured bicycle seat is required to be able to adapt to certain people and riding situations. This is achieved by providing an articulated section in the support device of the seat. The articulated section is especially placed at a distance from the actual seat. As a result, the rider no longer primarily sits on his pubic bone, rather, he sits on his ischiums or on his buttocks. This corresponds to the natural requirements of the human buttocks and thus increases the riding comfort, especially during longer rides.
The intervention entails implementing a shift schedule which abolishes quick returns for a six-month intervention period. The number of quick returns in the various hospital units in this trial varies from 329-2356 per year. The intervention means that this number is abolished or reduced as much as possible. For practical reasons it is reasonable to expect that for many of the units it may be a matter of reducing rather than completely abolishing quick returns, as ensuring adequate staffing (e.g., due to sickness absence), often on short-notice make it impossible to comply with the rule of avoiding quick returns. The human resources department at the hospital assisted shift planners in scheduling shift schedules without quick returns.